



ORIGINAL ARTICLE

Respiratory sleep disturbance in children and adolescents with cystic fibrosis



A.M. Silva^{a,*}, A. Descalço^a, M. Salgueiro^a, L. Pereira^b, C. Barreto^c,
T. Bandeira^{a,b}, R. Ferreira^{a,b}

^a Pediatric Lung Function and Sleep Laboratory, Hospital de Santa Maria, CHLN, Lisbon Academic Medical Center, Portugal

^b Respiratory Unit, Department of Pediatrics, Hospital de Santa Maria, CHLN, Lisbon Academic Medical Center, Portugal

^c Department of Pediatrics, Hospital de Santa Maria, CHLN, Lisbon Academic Medical Center, Portugal

Received 10 November 2015; accepted 6 February 2016

Available online 3 April 2016

KEYWORDS

Sleep disturbance;
Polysomnography;
Spirometry;
Cystic fibrosis;
Children

Abstract Sleep disturbance has been described in cystic fibrosis (CF) patients as relevant to clinical and lung function predictive factors helping to improve the diagnosis and early intervention. Related paediatric studies are scarce.

Objective: To describe respiratory sleep disturbance (RSD) and its association with spirometric indices in a population of CF children. A second aim was to determine if spirometric indices and wake-time SpO₂ are predictors of sleep disturbance.

Methods: A cross-sectional study involving 33CF paediatric patients. All participants underwent in-lab polysomnography (PSG), pulse oximetry and spirometry. A standardized sleep questionnaire was completed for each patient. Two subgroups were considered: I – Normal (FEV₁ > –1.64 z-score); II – Obstructed (FEV₁ ≤ –1.64 z-score).

Results: Participant's median age was 12 (6–18) years, 16 (48.5%) were male. Twenty-nine patients (87.9%) presented sleep complaints. Sleep efficiency was reduced; sleep latency and waking after sleep onset (WASO) increased. N1 increased, N2, N3, REM and awakenings were normal. The apnoea–hypopnoea index was 0.6/h (sd 0.9); respiratory disturbance index (RDI) was 6.6/h (sd 5.2). Mean awaking (97% (sd 1.1)) and sleep SpO₂ (95% (sd 2.7)) were normal;

Abbreviations: AHI, apnoea/hypopnoea index; BMI, body mass index; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ERS, European Respiratory Society; FEF_{25–75}, forced expiratory flow between 25% and 75% of maximal expiratory flow; FEV₁, forced expiratory volume in 1 s; FL, flow limitation; FVC, forced vital capacity; HSM, Hospital de Santa Maria; N1, sleep stage 1; N1%TST, time in N1 as a percentage of total sleep time; N2, sleep stage 2; N2%TST, time in N2 as a percentage of total sleep time; N3, sleep stage 3; N3%TST, time in N3 as a percentage of total sleep time; NREM, non REM sleep; ODI, oxygen desaturation index; PSG, polysomnography; RDI, respiratory disturbance index; REM, rapid eye movement; REM%, time in REM as a percentage of total sleep time; REML, REM latency; RSD, respiratory sleep disturbance; SE, sleep efficiency; SL, sleep latency; SQ, sleep questionnaire; SpO₂, pulse oximetry; SpO₂mean, mean pulse oximetry value; SpO₂min, minimal pulse oximetry value; tCO₂, transcutaneous CO₂; TST, total sleep time; W, wake; WASO, wake after sleep onset.

* Corresponding author.

E-mail addresses: anammsilva@gmail.com (A.M. Silva), andriadescalco@hotmail.com (A. Descalço), marisalsalgueiro@hotmail.com (M. Salgueiro), mluisafpereira@gmail.com (L. Pereira), celeste.barreto@chln.min-saude.pt (C. Barreto), terb@sapo.pt (T. Bandeira), rosariotferreira@sapo.pt (R. Ferreira).

<http://dx.doi.org/10.1016/j.rppnen.2016.02.007>

2173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

mean nocturnal oximetry desaturation index was 2.36/h; minimal nocturnal SpO₂ was 89% (sd 4.1).

We found associations between mean nocturnal SPO₂ and mean values of FEV₁ ($r=0.528$; $p=0.002$) and FEF₂₅₋₇₅ ($r=0.426$; $p=0.013$). There were significant differences in nocturnal SpO₂ between normal and obstructed patients ($p<0.000$). PSG data correlated with the questionnaire answers for night awakenings and WASO ($p=0.985$) and difficult breathing during sleep and RDI ($p=0.722$).

This study points to most CF children having sleep complaints, and highlights the correlation between subjective assessment of sleep and PSG and spirometric results. Awake-time SpO₂ and spirometric values are possible risk predictors for nocturnal desaturation.

© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Sleep disturbance in cystic fibrosis (CF) patients has been increasingly recognized in all ages.¹⁻⁶ Respiratory sleep disturbance (RSD), with nocturnal desaturation^{4,7} and hypoventilation⁶ has been described in association with chronic lung disease and respiratory failure^{1,8} as well as with cough^{9,10} and upper airway obstruction.^{11,12} Sleep fragmentation and poor sleep quality are also reported.^{6,11,13}

It is not clear in what way RSD modulates the clinical course of children with CF,¹⁴ but it interferes with quality of life.¹¹ Other factors contributing to poor sleep quality in CF patients are night anguish, fear of death, drug effects and the need for nocturnal therapies.^{11,14,15}

Lung function measures, in particular spirometric indices, are critical for the assessment and management of CF patients; they are a primary diagnostic, therapeutic and prognostic endpoint.¹⁶⁻²⁰ Few reports have evaluated lung function tests and awake pulse oximetry (SpO₂) as predictors of sleep disturbance in children with CF and the results are contradictory.^{6,14,15,21}

Our main objective was to describe respiratory sleep disturbance in a population of clinically stable children and adolescents with CF. Our aim was also to identify if spirometric indices (FEV₁, FEF₂₅₋₇₅, FEV₁/FVC) and awake-time SpO₂ could be predictors of sleep disturbance.

Methods

This was an observational, prospective, cross-sectional and descriptive-analytical study. Children were recruited from the Paediatric Unit of a Specialized Centre for Cystic Fibrosis of a Tertiary Care Hospital, between February and October 2013. Written informed consent was obtained from parents of children under 16 years-old and from patients above that age.

All but one patient had CF confirmed by the presence of two transmembrane regulator (CFTR) mutations; one child had one CFTR mutation with a sweat chloride test >60 mmol/l, associated with characteristic phenotype; twenty-one (63.6%) were homozygote for the mutation ΔF508.

Clinical stability, defined as the absence of respiratory exacerbations and increased tiredness, maintenance of weight gain and stable FEV₁, for a month previous to the study was required for inclusion. Exclusion criteria were chronic respiratory failure or being unable to cooperate during spirometry.

Body mass index (BMI) was assessed and reported as z-score.

All participants or their parents completed a standardized sleep questionnaire (SQ) before polysomnography (PSG); daytime SpO₂ and spirometry were performed the following day.

SQ is a non validated but routinely applied questionnaire at the Paediatric Sleep Laboratory. SQ has been developed as a rapid screening tool based on the Paediatric Sleep Questionnaire²² and the Sleep Apnea Questionnaire.²³ It includes questions about sleep quality, night-time and daytime symptoms and signs of RSD and sleep disturbance, and associated events like parasomnias.

In-lab PSG (SomnoScreen® Plus TM Domino Software, v.2.3.1) was performed for a minimum of 7h. The following parameters were recorded at the same time: six channel electroencephalogram, bilateral electrooculogram, anterior tibialis and chin electromyogram, electrocardiogram, oronasal thermistor airflow detection, nasal cannula transducer, body position, tracheal microphone, thoracic and abdominal movements using respiratory effort bands and pulse oximetry.

A desaturation event was defined as a decrease of SpO₂ ≥ 3%. Mean and minimum SpO₂ were determined as well as the percentage of total sleep time with SpO₂ < 90%. Analysis of sleep stages, arousals, movements and respiratory events was performed according to the American Academy of Sleep Medicine manual.²⁴⁻²⁶ Flow limitation was defined as a flattening of the inspiratory portion of the flow waveform detected by nasal cannula pressure during sleep without criteria of hipopnoea. The sleep data included were: time in bed, defined as time from lights out to lights on; sleep efficiency (SE), calculated as total sleep time divided by the total time in bed; sleep latency (SL), defined from lights out until the first epoch of any sleep stage; wake after sleep onset (WASO), defined as time spent awake between the sleep onset and the end of sleep; REM latency (REML)

defined as time between sleep onset to the first REM epoch. Sleep stages duration is presented as a percentage of total sleep time (TST).

Normative values according to Beck et al.,²⁷ were adopted; respiratory disturbance index (RDI) was defined as the sum of all respiratory events (flow limitations, apnoeas, hipopnoeas) and was interpreted according to Uliel.²⁸

Continuous transcutaneous CO₂ (SENTEC® digital V-ST-AT2.02) monitoring was performed to assess median and maximal tcCO₂.

Awake SpO₂ was assessed by digital measure with Nonin® 7500 (Nonin Medical Inc., Plymouth, MN, USA), the mean of at-rest values obtained over one-minute period of the plethysmographic wave form stability, with the patient in a sitting position.

Spirometry (Jaeger Master Screen PFT® – Viasys Healthcare, v.5.3.0) was performed according to the American Thoracic Society and the European Respiratory Society criteria²⁹ for patients ≥6 years of age; values were expressed in z-scores according to the equations from the growing lung initiative (growinglungs.org.uk).³⁰ The sample was then stratified according to FEV₁ as Group I, within normal clinical range values (z-score > -1.64) and Group II, classified as obstructive (z-score ≤ -1.64).

Descriptive statistics, correlations by Pearson's coefficient, Mann-Whitney test and K-Smirnov test were performed as appropriate and a significance level of 5% was considered. Statistical Package for the Social Sciences 21.0 (SPSS, Chicago, IL, USA) was used for all tests.

Results

Forty-five CF patients aged between 6 and 18 years old were recruited and 33 were included. Eight patients refused to participate in the study and four were excluded: two had home ventilation or oxygen therapy, one an unconfirmed diagnosis and another was not clinically stable during the study period. Sixteen (48.5%) patients were male; the median age was 12 (6–18) years-old. Median age at CF

diagnosis was 11 (0–118) months. Average BMI z-score was normal (-0.35 ± 0.78) (Table 1).

Questionnaire results

Twenty-nine patients (87.9%) reported poor sleep quality and/or RSD: 19 (57.6%) complained of impaired sleep onset and awaking more than twice per night; 15 (45.5%) reported difficult breathing during sleep and 19 (57.6%) reported snoring, 29 (87.9%) stated they stopped breathing during sleep and 21 (63.7%) were mouth breathers. Daytime symptoms were rare, and the most common was inattentive behaviour (39.4%). More than half of the patients mentioned sleep talking (54.5%). Parasomnias were not relevant.

Polysomnography results

Sleep structure

Mean TST was 6.7 ± 0.59 h, with decreased SE ($79.91 \pm 10.98\%$) and increased SL (37 ± 33.07 min) and WASO (65.65 ± 39.54 min). REML was normal (143.39 ± 80.09 min), and so was stages distribution N2 ($43.8 \pm 8.9\%$ TST), N3 ($26.4 \pm 7.8\%$ TST) and REM ($19.32 \pm 6.3\%$ TST); N1 was slightly elevated ($5.88 \pm 5.4\%$ TST) and showed a negative association with sleep efficiency ($r = -0.561$; $p = 0.001$). The arousal index (5 ± 2.39 /h) was within normal range (Table 2).

Respiratory events

Mean apnoea/hypopnoea index (AHI) was 0.6 ± 0.9 /h of sleep; mean flow limitations (44.9 ± 38.7) and RDI (6.6 ± 5.2 /h) were slightly increased (Table 2). Twenty-nine (87.9%) patients presented paradoxical breathing and eight (24.2%) snored.

Nocturnal gas exchange

Mean awake ($97 \pm 1.1\%$) and nocturnal SpO₂ ($95 \pm 2.7\%$) were in the normal range. Mean oxygen desaturation index (ODI) was 2.36 ± 2.40 /h; minSpO₂ was $89\% \pm 4.1\%$ (Table 2). Average median values of tcCO₂ was normal (40.18 ± 4.8 mmHg). tcCO₂ mean maximal value was $45.39 (\pm 5.16)$ mmHg.

Table 1 Demographics and spirometry results.

	Total population N = 33	Group I N = 13	Group II N = 20	p ^a
<i>Characteristics of the patients</i>				
Age (years)	12.27 ± 3	11.62 ± 3.65	13 ± 3.07	0.576
Diagnostic age (months) (median(min-max))	11 (0-118)	6 (1-118)	14.5 (0-108)	0.654
Males (n) (%)	16 (48.5)	6 (46.1)	10 (50)	–
BMI z-score	-0.35 ± 0.78	0.11 ± 0.79	-0.59 ± 0.68	0.327
<i>Spirometry</i>				
FVC z-score (mean)	-1.09 ± 1.46	0.25 ± 0.97	-1.96 ± 0.96	0.065
FEV ₁ z-score (mean)	-1.76 ± 1.60	-0.12 ± 0.95	-2.83 ± 0.81	0.001
FEV ₁ /FVC z-score (mean)	-1.31 ± 1.04	-0.68 ± 0.62	-1.73 ± 1.05	0.080
FEF ₂₅₋₇₅ z-score (mean)	-2.06 ± 1.62	-0.80 ± 1.22	-2.89 ± 1.25	0.002

FVC – forced vital capacity; FEV₁ – forced expiratory volume in 1 s; FEF₂₅₋₇₅ – forced expiratory flow between 25% and 75% of maximal expiratory flow.

^a Mann-Whitney test.

Table 2 Polysomnography analysis.

Sleep structure		Respiratory events	
TST (h)	6.70 ± 0.59	AHI (n/h)	0.60 ± 0.90
SE (%)	79.91 ± 10.98	FL (n)	44.90 ± 38.70
SL (min)	37.95 ± 33.01	RDI (n/h)	6.60 ± 5.20
W (min)	103.61 ± 53.84	Sleep SpO ₂ mean (%)	95.00 ± 2.70
WASO (min)	65.65 ± 39.54	Sleep SpO ₂ min (%)	89.00 ± 4.10
REML (min)	143.39 ± 80.09	SpO ₂ < 90 (%TST)	1.75 ± 6.80
N1 (%TST)	5.88 ± 5.40	ODI (n/h)	2.36 ± 2.40
N2 (%TST)	48.38 ± 8.18	Awake SpO ₂ (%)	97.00 ± 1.10
N3 (%TST)	26.40 ± 7.84	tcCO ₂ median (mmHg)	40.18 ± 4.80
REM (%TST)	19.32 ± 6.34	tcCO ₂ max (mmHg)	45.39 ± 5.16
Sleep arousals (n/h)	5.00 ± 2.39		

TST – total sleep time; SE – sleep efficiency; SL – sleep latency; W – wake; WASO – wake after sleep onset; REML – REM latency; N1 (%TST) – time in N1 (%); N2 (%TST) – time in N2 (%); N3 (%TST) – time in N3 (%); REM (%TST) – time REM (%); AHI – apnoea/hypnoea index; FL – flow limitation; RDI – respiratory disturbance index; ODI – oxygen desaturation index; Sleep SpO₂ mean – mean sleep pulse oximetry; Sleep SpO₂ min – minimal sleep pulse oximetry; tcCO₂ – transcutaneous CO₂ (median and maximal).

Awake and sleep SpO₂ were positively correlated ($r=0.426$; $p=0.064$) and although without statistical significance this may be clinically relevant. The mean ODI showed moderate negative correlation with minimal nocturnal SpO₂ ($r=-0.532$; $p=0.001$) and with mean nocturnal SpO₂ ($r=-0.358$; $p=0.041$). A negative moderate correlation was found between awake SpO₂ and AHI ($r=-0.469$; $p=0.006$).

Spirometric indices analysis

Mean global z-score was reduced for FEV₁ (-1.76 ± 1.60) and for FEV₂₅₋₇₅ (-2.06 ± 1.62). Thirteen patients had FEV₁ within the normal range (Group I) and 20 patients had FEV₁ ≤ -1.64 z-score and were classified as obstructed (Group II). Mean z-score for FVC and for FEV₁/FVC was normal (Table 1).


Polysomnographic and spirometric results association analysis

As defined by FEV₁, compared to Group I, patients from Group II showed a trend towards a lower mean SE ($81.03 \pm 12.05\%$ vs $79.17 \pm 10.98\%$; $p=0.478$), more sleep arousals ($4.69 \pm 1.63/h$ vs $5.12 \pm 2.69/h$; $p=0.235$) and increased WASO (52.58 ± 35.06 min vs 74.12 ± 40.79 min; $p=0.169$), although none reached statistical significance (Table 3).

No differences between groups were found for respiratory events during sleep. A significant difference was found for mean sleep SpO₂, lower in Group II ($94.10 \pm 3.21\%$ vs $96.53 \pm 0.77\%$; $p < 0.000$); minimal sleep SpO₂ ($88.75 \pm 4.77\%$ vs 90.38 ± 3.01) was also without statistical significance ($p=0.456$). Mean median tcCO₂ was normal in both groups (Table 3). Analysis for FEV₂₅₋₇₅ presented similar results.

FEV₁ was positively associated with average sleep SpO₂ ($r=0.528$; $p=0.002$) (Fig. 1) and minimal sleep SpO₂ ($r=0.405$; $p=0.019$). A moderate, negative association between awake SpO₂ and AHI ($r=-0.469$; $p=0.006$) was found.

Maximal tcCO₂ was negatively and moderately associated with average sleep SpO₂ ($r=-0.387$; $p=0.026$).

**Figure 1** Association of FEV₁ and sleep SpO₂.

Polysomnography data and sleep questionnaire Association analysis

PSG data significantly correlated with the questionnaire answers for night awakenings and WASO ($p=0.985$), and for difficult breathing during sleep and RDI ($p=0.722$). Difficulty in falling asleep correlated moderately with SL ($p=0.345$). No association was found for snoring reported in the SQ and in the PSG ($p=0.039$) or for breathing interruption during sleep ($p=0.039$) and AHI ($p=0.049$).

Discussion

To the best of our knowledge this is the first study in a CF Portuguese Paediatric population to evaluate sleep disturbance and to try to relate it to spirometric indices, a clinical diagnostic and prognostic relevant endpoint.¹⁶

There are some studies involving adult CF patients and CF children but only during acute illness or with higher clinical severity.^{1,7,13,31} Most studies presented limitations such as small population samples, sleep assessment performed only through sleep questionnaires and/or evaluated by pulse oximetry analysis.^{6,15,32} Only a few studies assessed sleep with PSG or quantified severity of lung disease with an objective measure like spirometry, as we did.^{1,7,11,13,33}

Table 3 Polysomnography events according to FEV₁ z-score group analysis.

	FEV ₁ z-score		<i>p</i> ^a
	Group I N = 13	Group II N = 20	
TST (h)	6.81 ± 0.81	6.70 ± 1.11	0.758
SE (%)	81.03 ± 12.05	79.17 ± 10.48	0.478
SL (min)	49.88 ± 45.97	30.20 ± 18.45	0.478
W (min)	102.46 ± 64.97	104.35 ± 47.07	0.501
WASO (min)	52.58 ± 35.06	74.15 ± 40.79	0.169
REML (min)	136.31 ± 77.54	148.00 ± 83.36	0.813
N1 (%TST)	6.19 ± 5.89	5.68 ± 5.21	0.899
N2 (%TST)	46.29 ± 8.86	49.74 ± 7.62	0.181
N3 (%TST)	27.56 ± 7.97	25.65 ± 7.87	0.524
REM (%TST)	19.90 ± 6.56	18.94 ± 6.33	0.548
Sleep arousals (n/h)	4.68 ± 1.63	5.12 ± 2.69	0.235
AHI (/h)	0.44 ± 0.48	0.72 ± 1.09	0.785
FL (n)	58.08 ± 48.15	36.45 ± 29.55	0.221
RDI (n/h)	8.69 ± 7.23	5.30 ± 2.77	0.298
Sleep SpO ₂ mean (%)	96.53 ± 0.77	94.10 ± 3.21	0.000
Sleep SpO ₂ min (%)	90.38 ± 3.01	88.75 ± 4.70	0.456
ODI (n/h)	2.65 ± 2.15	2.17 ± 2.58	0.250
Awake SpO ₂ (%)	97.23 ± 1.01	96.90 ± 1.20	0.758
tcCO ₂ median (mmHg)	40.76 ± 3.85	39.80 ± 5.27	0.598
tcCO ₂ max (mmHg)	45.66 ± 5.38	45.26 ± 5.02	0.524

^a Mann-Whitney test.

TST – total sleep time; SE – sleep efficiency; SL – sleep latency; W – wake; WASO – wake after sleep onset; REML – REM latency; N1 (%TST) – time in N1 (%); N2 (%TST) – time in N2 (%); N3 (%TST) – time in N3 (%); REM (%TST) – time REM (%); AHI – apnoea/hypopnoea index; FL – flow limitation; RDI – respiratory disturbance index; ODI – oxygen desaturation index; sleep SpO₂ mean – mean sleep pulse oximetry; sleep SpO₂ min – minimal sleep pulse oximetry; tcCO₂ – transcutaneous CO₂ (median and maximal).

In this study, 87.9% of clinically stable children between six and eighteen years, with normal or mildly affected lung function, were identified as having sleep disturbance, either respiratory or of the sleep structure. These alterations correspond to subjectively diminished quality of sleep, even with slight anomalies of PSG values. These findings are consistent with the majority of other reports showing that CF patients have lower sleep efficiency and quality.^{6,11,13,15,34}

Difficulty in breathing during sleep was reported in almost half of our patients and had a positive association with RDI. Night awakenings and WASO (*p* = 0.985) were also associated. These results confirm what was suggested by Milross,³³ that even a simple questionnaire like the one used in this study has an important role in sleep disturbance screening in CF patients.

The in-lab first night effect must be considered when evaluating SE and SL disturbance: sleep in the laboratory can influence sleep onset and duration, as showed by Verhulst et al.³⁵ who described the first night effect in children with RSD. This study included predominantly adolescents, and sleep phase delay associated with this age group may act as a confounder to the sleep onset and duration compromise.³⁶ As in our study, Perin and Milross also found higher wakefulness and sleep latency leading to lower sleep efficiency in CF patients.^{13,34}

In the present study, arousal index was normal but higher in the group with higher respiratory compromise evaluated by spirometric indices, as described by Naqvi and Danczyk.^{11,31}

N1 was elevated and showed a negative association with sleep efficiency, pointing to sleep fragmentation. The higher WASO was more evident in the group with abnormal FEV₁, but no significant correlation was found.

Naqvi et al.¹¹ described an association between the magnitude of sleep structure disruption and the severity of lung disease, but not with hypoxaemia or hypoventilation during sleep, which is similar to our results. We could not stratify patients by severity levels because of the small size of the sample, but sleep structure compromise showed a tendency to be more common in the group with lower FEV₁.

Ramos et al. studied a stable paediatric CF population and described important complaints about sleep quality and significant architecture disruption as well as prevalent respiratory sleep disturbance and episodes of nocturnal desaturation.^{14,15} No significant respiratory events were registered in our study. The absence of major respiratory disturbance can be explained by the young age of the patients, the clinical stability and lung function preservation in this sample. Perin did not find higher prevalence of respiratory sleep disturbance either, in an adult CF population with similar characteristics.³⁴ We found a lower SpO₂ during sleep, as expected, and although not in the pathological range, there were some sleep desaturations, which are in accordance with other studies: Ramos et al., in a group of school age CF children and adolescents identified an intermittent fall of nocturnal SpO₂ and normal or minor lung function compromise.¹⁴ Naqvi has also found reduced minimal SpO₂,

without significant respiratory events. This data is consistent with our findings, as we identified diminished minimal SpO₂ associated with ODI, but without significant respiratory events. This author states that apnoea or hypopnoea is uncommon in CF, even in the presence of moderate to severe lung disease.¹¹

Like Milross,¹³ we found an association between awake and sleep SpO₂, that even without statistical significance, can point towards wake oximetry as a possible predictive tool for nocturnal hypoxaemia. However, our sample is small and inter-patients variability of nocturnal SpO₂ was high, which precludes us from clearly stating this.

Another interesting finding was the association of awake SpO₂ with AHI, which favours the importance of wake oximetry to anticipate the occurrence of nocturnal respiratory events. These findings must be confirmed in larger samples and more heterogeneous populations.

The mild alterations of lung function can be explained by the clinical stability of this paediatric patient sample, due to progress made in CF patient care that postpones more severe disease stages for adult age.³⁴ Our analysis was done with spirometric indices (FEV₁, FEF₂₅₋₇₅ and FEV₁/FVC) above or under the cut-off for normal stated clinical z-scores and we did not include in this study the analysis of other clinical or radiological severity scores, which may limit the extrapolation of results. However, spirometry by itself is accepted as a marker of disease severity,^{18-20,28,37} conferring reliability to our findings.

We identified significant lower sleep SpO₂ in patients with FEV₁ z-score under normal range, which indicates spirometric indices as possible predictors of nocturnal desaturation, as described in other studies.^{4,7,15,38,39}

As in other studies, we did not find any association between sleep architecture parameters and spirometry.^{4,7,39}

This study has a few limitations: the in-lab night study may not reflect the usual sleep behaviour; patient stability may underestimate the relationship between sleep disturbance and disease severity; the small sample dimension precluded us from doing severity stratification, which could have been more accurate in identifying sleep and wake respiratory compromise; we did not use a quality of life questionnaire, which could have provided important data on sleep disturbance consequences.

Nevertheless this study forms the basis for a relevant discussion about sleep compromise in a paediatric "healthy" group of CF patients. As sleep quality is related to quality of life and maintenance of good clinical condition, the results of this study indicate that sleep evaluation must be considered in the routine assessment of CF patients from early stages of disease.

Conclusion

This study showed that most CF children have complaints about sleep quality, identified by a SQ and confirmed by PSG.

No clear association between sleep structure disruption and the severity of lung disease was found, but although not remarkable, nocturnal O₂ desaturation occurred in a clinically stable sample of CF paediatric patients associated with respiratory disease severity assessed by spirometry.

Further studies are needed in more representative populations with a higher clinical severity span to confirm our results.

Ethical responsibilities

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work centre on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

This study would not be possible without children and parents participation, to all thank you.

We also acknowledge Teresa Fonseca, PhD, whose contribution was relevant for the analysis performed.

References

1. Amin R, Bean J, Burklow K, Jeffries J. The relationship between sleep disturbance and pulmonary function in stable pediatric cystic fibrosis patients. *Chest*. 2005;128:1357-63.
2. Boergers J, Koinis-Mitchell D. Sleep and culture in children with medical conditions. *Pediatr Psychol J*. 2010;35:915-26.
3. Marcus CL. Sleep disordered breathing in children. *Am J Respir Crit Care Med*. 2001;164:16-30.
4. Castro-Silva C, Bruin V, Cavalcante AG. Nocturnal hypoxia and sleep disturbances in cystic fibrosis. *Pediatr Pulmonol*. 2009;44:1143-50.
5. Katz E. Cystic fibrosis and sleep. *Clin Chest Med*. 2014;35:495-504.
6. Fauroux B, Pepin J, Boelle P, Cracowski C, Murriss-Espin M, Nove-Josserraand R, et al. Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. *Arch Dis Child*. 2012;17:960-6.
7. Frangolias D, Wilcox P. Predictability of oxygen desaturation during sleep in patients with cystic fibrosis. *Chest*. 2001;119:434-41.
8. Loughlin GM, Carroll JL. Sleep and respiratory disease in children. [Book author] Carroll JL Loughlin GM. *Sleep and respiratory disease in children. In Principles and Practice of Sleep Medicine in the Child*. London: Saunders Company; 1995. p. 217-30.
9. Kerem E, Reisman J, Corey J, Canny J, Levison J. Prediction of mortality in patients with cystic fibrosis. *N Engl J Med*. 1992;326:1187-91.
10. van der Giessen L, Loeve M, de Jongste J, Hop W, Tiddens H. Nocturnal cough in children with stable cystic fibrosis. *Pediatr Pulmonol*. 2009;44:859-65.

11. Naqvi SK, Sotelo C, Murry L, Simakajornboon N. Sleep architecture in children and adolescents with cystic fibrosis and the association with severity of lung disease. *Sleep Breath.* 2008;12:77–83.
12. Ramos R, Salles C, Gregório PB, Barros AT, Santana A, Araújo-Filho JB, et al. Evaluation of the upper airway in children and adolescents with cystic fibrosis and obstructive sleep apnea syndrome. *Int J Pediatr Otorhinolaryngol.* 2009;73:1780–8.
13. Milross MA, Piper A, Dobbin CJ, Bye P, Grunstein R. Sleep disordered breathing in cystic fibrosis. *Sleep Med Rev.* 2004;8:295–308.
14. Ramos RT, Salles C, Daltro CH, Santana MA, Gregório PB, Acosta AX. Sleep architecture and polysomnographic respiratory profile of children and adolescents with cystic fibrosis. *J Pediatr (Rio J).* 2011;87:63–9.
15. Ramos R, Santana M, Almeida P. Nocturnal hypoxemia in children and adolescents with cystic fibrosis. *J Bras Pneumol.* 2013;39:667–74.
16. Tiddens H, Puderbach M, Venegas JG, Ratjen F, Donaldson SH, Davis SD, et al. Novel outcome measures for clinical trials. *Pediatr Pulmonol.* 2015;50:302–15.
17. Stanojevic S, Stocks J, Bountziouka V, Aurora P, Kirkby J, Bourke S, et al. The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry. *J Cyst Fibros.* 2014;13:319–27.
18. Corey M, Edwards L, Levison H. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. *J Pediatr.* 1997;131:809–14.
19. Cymbarknoh MC, Shoseyov D, Kerem E. Managing cystic fibrosis. *Am J Respir Crit Care Med.* 2011;183:1463–2147.
20. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, et al. Infection, inflammation, and lung function decline in infants with Cystic Fibrosis. *Am J Respir Crit Care Med.* 2011;184:75–81.
21. Van Der Giessen L, Bakker M, Joosten K, Hop W, Tiddens H. Nocturnal oxygen saturation in children with stable cystic fibrosis. *Paediatr Pulmonol.* 2012;47:1123–30.
22. Chervin RD, Hedger KM, Dillon JE, Pituch KJ. Pediatric Sleep Questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. *Sleep Med.* 2000;1:21–32.
23. Peeke K, Hershberger M, Marriner J. Obstructive sleep apnea syndrome in children. *Pediatr Nurs.* 2006;32:489–94.
24. Berry R, Budhiraja R, Gottlieb D, Gozal D. Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for scoring of sleep and associated events. *J Clin Sleep Med.* 2012;8:597–619.
25. Iber C, Ancoli-Israel S, Chesson A, Quan S. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. 1st ed. American Academy of Sleep Medicine; 2007.
26. Berry RB, Brooks R, Gamaldo CE, Harding SM, Marcus CL, Vaughn BV. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, version 2.0. Darien, IL: American Academy of Sleep Medicine; 2012 www.aasmnet.org
27. Beck S, Marcus C. Pediatric polysomnography. *Sleep Med Clin.* 2009;4:393–406.
28. Uliel S, Tauman R, Greenfeld M, Sivan Y. Normal polysomnography respiratory values in children and adolescents. *Chest.* 2004;125:872–8.
29. Miller ML, Hankinson J, Brusasco V. Standardisation of spirometry – American Thoracic Society Documents. *Eur Respir J.* 2005;26:319–38.
30. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hal GL, Culver, et al. Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95 years age range: the Global Lung Function 2012 equations. *Eur Respir J.* 2012;40:1324–43.
31. Dancey DR, Tullis ED, Heslegrave R, Thornley K, Hanly PJ. Sleep quality and daytime function in adults with cystic fibrosis and severe lung disease. *Eur Respir J.* 2002;19:504–10.
32. Jankelowitz L, Reid KJ, Wolfe L, Cullina J, Zee PC, Jain M. Cystic Fibrosis patients have poor sleep quality despite normal sleep latency and efficiency. *Chest.* 2005;127:1593–9.
33. Milross MA, Pipper AJ, Norman M, Wilson G, Grunstein R, Sullivan, et al. Predicting sleep-disordered breathing in patients with cystic fibrosis. *Chest.* 2001;120:1239–45.
34. Perin C, Fagundes S, Casaroto FC, Pinotti A, Barreto S, Dalcin P. Sleep findings and predictors of sleep desaturation in adult cystic fibrosis patients. *Sleep Breath.* 2012;16:1041–8.
35. Verhulst SL, Schrauwen N, De Backer WA, Desager KN. First night effect for polysomnographic data in children and adolescents with suspected sleep disordered breathing. *Arch Dis Child.* 2006;91:233–7.
36. Carskadon MA, Vieira C, Acebo C. Association between puberty and delayed phase preference. *Sleep.* 1993;16:258–62.
37. Farrell P, Rosenstein B, White T, Accurso F, Castellani C, Cutting G, et al. Guidelines for diagnosis of Cystic Fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report. *J Pediatrics.* 2008;153:S4–14.
38. Pond SP, Conway MN. Nocturnal desaturation and spirometric parameters in adults with cystic fibrosis. *Arch Dis Child.* 1995;50:539–42.
39. Uyan ZS, Ozdemir N, Ersu R, Akpınar I, Keskin S, Cakır E, et al. Factors that correlate with sleep oxygenation in children with cystic fibrosis. *Pediatr Pulmonol.* 2007;42:716–22.